Imeglimin - A New Oral Anti-Diabetic that Targets the Three Key Defects of type 2 Diabetes
Published inJournal of diabetes & metabolism, vol. 2, no. 4
Publication date2011
Affiliation entities
Citation (ISO format)
FOUQUERAY, Pascale et al. Imeglimin - A New Oral Anti-Diabetic that Targets the Three Key Defects of type 2 Diabetes. In: Journal of diabetes & metabolism, 2011, vol. 2, n° 4. doi: 10.4172/2155-6156.1000126
Main files (1)
Article (Published version)
Identifiers
- PID : unige:47301
- DOI : 10.4172/2155-6156.1000126
Additional URL for this publicationhttp://www.omicsonline.org/2155-6156/2155-6156-2-126.digital/2155-6156-2-126.html
Journal ISSN2155-6156